Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-17-012350
Filing Date
2017-05-08
Accepted
2017-05-08 20:20:59
Documents
1
Period of Report
2017-05-04

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 6336
  Complete submission text file 0000899243-17-012350.txt   8691
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Reporting) CIK: 0001114448 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-32587 | Film No.: 17824112
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Reporting) CIK: 0001297709 (see all company filings)

State of Incorp.: D0 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-32587 | Film No.: 17824113

Mailing Address 19 FIRSTFIELD ROAD GAITHERSBURG MD 20878
Business Address 19 FIRSTFIELD ROAD GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Issuer) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations